Quick answer on cagrilintide prescription in Australia
- Cagrilintide is not TGA-approved at the time of writing and is not on the PBS.
- A prescription is required for any therapeutic use. Because it’s unapproved, prescribers must use the TGA’s Special Access Scheme (SAS Category B) or become an Authorised Prescriber (AP).
- Personal importation is only lawful with a valid Australian script and strict conditions—and still carries seizure and quality risks.
- Many clinics do not offer cagrilintide yet. Where access is offered, supply is private-pay and typically costly.
- Approved alternatives available now include semaglutide and tirzepatide for eligible patients.
What cagrilintide is and its current status in Australia
Cagrilintide is an amylin analogue being investigated for weight management, including in combination with semaglutide (“CagriSema”). While clinical data continue to evolve, cagrilintide by itself or in fixed‑dose combination has not received TGA approval in Australia at the time of writing. That means there is no standard pharmacy brand on the shelf and no PBS subsidy.
Any medical use therefore relies on unapproved medicine pathways and the willingness of a suitably qualified Australian prescriber to supervise therapy and arrange compliant supply.
When a script is required (and what it must include)
For human therapeutic use, cagrilintide sits behind an Australian prescription. Because it is unapproved:
- Prescription must be issued by an Australian‑registered prescriber familiar with obesity medicine or endocrine care.
- TGA pathway: The prescriber must submit SAS Category B for individual patients or hold Authorised Prescriber approval for the indication.
- Quality and sourcing must meet TGA expectations (e.g., GMP‑compliant manufacturer, appropriate documentation).
- Pharmacy supply is generally via a pharmacy or importer set up to handle unapproved medicines; routine compounding is often not available.
Access pathways compared
Here’s how Australians typically evaluate access to cagrilintide today:
- Clinical trials: May offer monitored access at no or reduced cost; eligibility is strict and locations limited.
- SAS Category B: Case‑by‑case approval via your doctor; requires clinical justification, informed consent and compliant product sourcing.
- Authorised Prescriber (AP): A prescriber with pre‑approval for a defined patient group; still private‑pay and dependent on supply chain.
- Personal Importation Scheme: Possible only with an Australian script and strict limits (max 3 months’ supply, personal use, original packaging, documentation). Seizure and quality risks remain.
- Wait for approval: If/when TGA approval is granted, standard pharmacy supply and clearer guidance will follow.
If you need results sooner, consider approved options with established supply: Wegovy (semaglutide), Ozempic (semaglutide) and Mounjaro (tirzepatide).
Who can prescribe cagrilintide in Australia?
In principle, any Australian‑registered doctor can apply to prescribe an unapproved medicine under SAS Category B; however, in practice, most access discussions occur with:
- Endocrinologists and obesity‑medicine prescribers experienced in metabolic care
- Specialist telehealth weight‑loss clinics with established SAS/AP processes
Many GPs prefer to use approved GLP‑1/dual agonists first. If you’re unsure where to start, see: Peptide Doctors Australia, Online Peptide Clinic Australia and Telehealth Peptide Clinic Australia.
Costs to expect (and how they compare)
- Consults: initial and follow‑ups with a prescribing clinician (private fees).
- Medication: unapproved medicine supply is not PBS‑subsidised and often higher than approved options due to import, QA and handling.
- Monitoring: periodic reviews, potential lab work and adverse‑event oversight.
For context on weight‑loss therapy budgets, see: Cagrilintide Cost Australia, Semaglutide Cost Australia and Tirzepatide Cost Australia.
Compliance basics and red flags to avoid
- No script, no sale: Selling or importing cagrilintide for human use without an Australian prescription is unlawful.
- Advertising limits: Clinics cannot directly advertise prescription‑only medicines to the public. Be cautious of promotional claims.
- Quality documentation: Expect GMP evidence, batch documentation and cold‑chain handling where applicable.
- Too‑good‑to‑be‑true pricing: Often signals grey‑market peptides with identity/sterility risks.
Learn how to judge sellers and claims: Buy Cagrilintide Australia (safer routes) and Peptide Advertising Laws Australia.
Next steps: compare your path to treatment
- Clarify goals and history (weight, comorbidities, prior GLP‑1/dual‑agonist use).
- Check eligibility for approved options first: Weight Loss Injections Australia, GLP-1 Australia Guide.
- If still considering cagrilintide, ask about SAS/AP feasibility, timelines and product sourcing.
- Understand private costs and monitoring plans before proceeding.
Frequently asked questions
Do you need a prescription for cagrilintide in Australia?
Yes. Any therapeutic use requires an Australian prescription and use of an unapproved‑medicine pathway (SAS Category B or Authorised Prescriber).
Is cagrilintide approved by the TGA or on the PBS?
No—at the time of writing it is unapproved and not PBS‑listed.
Can a GP prescribe it, or do I need a specialist?
Some GPs may apply via SAS, but access is more commonly managed by endocrinologists or obesity‑medicine prescribers experienced with unapproved medicines.
Can I import cagrilintide for personal use?
Only with a valid Australian script and strict Personal Importation Scheme conditions. Even then, seizure or refusal can occur, and quality must be demonstrated.
What about the semaglutide + cagrilintide combo (CagriSema)?
At the time of writing, the fixed‑dose combination is not TGA‑approved. Access would face the same unapproved‑medicine requirements.
What alternatives are available now?
Approved options include semaglutide (Wegovy; Ozempic off‑label for weight) and tirzepatide (Mounjaro), subject to eligibility and supply.
Where can I read more on risks and evidence?
See Cagrilintide Side Effects and Cagrilintide Benefits for what’s known and unknown.
Is this medical advice?
No. This page is general information. Always consult a qualified health professional for personalised advice.
Request help with cagrilintide access
Share a few details and a clinic partner can contact you to discuss eligibility, timelines and alternatives.
Prefer email? Contact us here.
Final takeaway
For Australians, cagrilintide remains an unapproved medicine. A prescription is required, and any lawful access depends on SAS/AP pathways and compliant supply chains. Many patients will qualify first for approved options like semaglutide or tirzepatide. If you still wish to explore cagrilintide, speak with an experienced prescriber about feasibility, costs and timelines.